Yamaha Debuts 2020 Proven Off-Road ATV Lineup
June 04, 2019 12:00 ET
|
Yamaha Motor Corp., USA
MARIETTA, Ga., June 04, 2019 (GLOBE NEWSWIRE) -- Yamaha Motor Corp., USA, announces its Proven Off-Road recreational, utility, and sport ATVs for model year 2020. All delivering Yamaha’s...
VANTAGE TAG SYSTEMS, a DSG Global Subsidiary, Completes Sales and Installations
December 11, 2018 12:53 ET
|
DSG Global Inc.
Company completes new installations around the world totaling over $1m Surrey, British Columbia, Dec. 11, 2018 (GLOBE NEWSWIRE) -- VANTAGE TAG SYSTEMS INC. (a division of DSG Global Inc.) (DSGT),...
DSG Global Inc. Upgrades Patented INFINITY SC System at Spectacular Hills Golf and Sports Club
September 20, 2018 09:58 ET
|
DSG Global Inc.
XFINITY SC continues to impress the best as demand for our product is at record levels Surrey, British Columbia, Sept. 20, 2018 (GLOBE NEWSWIRE) -- DSG GLOBAL INC. (DSGT), the world's leading...
Yamaha Announces 2019 ATV Lineup
June 06, 2018 10:00 ET
|
Yamaha Motor Corp., USA
KENNESAW, Ga., June 06, 2018 (GLOBE NEWSWIRE) -- Yamaha Motor Corp., USA, is expanding its family of Proven Off-Road Utility and Sport ATVs, providing superior Capability, Comfort and Confidence in...
Shortwave Infra-Red (SWIR) Camera Market is anticipated to grow at a CAGR of 7.1% during the forecast period of 2018-2025, Says Esticast Research and Consulting
February 19, 2018 06:51 ET
|
Esticast Research & Consulting
PUNE, India, Feb. 19, 2018 (GLOBE NEWSWIRE) -- “With the rapid development of imaging technology and optics, SWIR cameras would experience a hike in demand for various commercial as well...
Raptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis Patients
September 07, 2016 03:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...
Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR™ at the 39th European Cystic Fibrosis Conference
June 10, 2016 08:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...
Raptor Pharmaceutical to Hold First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, May 5, 2016, at 4:30 p.m. ET
April 28, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2016 financial results on Thursday, May 5,...
Raptor Pharmaceutical Launches QUINSAIR™ in Europe
April 11, 2016 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR™ (levofloxacin inhalation solution) in Germany and...
Raptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate Update
February 25, 2016 16:05 ET
|
Raptor Pharmaceutical Inc
2015 Global Net Revenue for PROCYSBI® of $94.2 Million Reported 2016 Global Net Revenue Guidance of $115 to $125 Million 2016 Anticipated PROCYSBI Growth of 25%-30% Year-Over Year Company to Host...